Anti-oxidant and anti-inflammatory activity of ketogenic diet. New perspectives for neuroprotection in alzheimer’s disease

The ketogenic diet, originally developed for the treatment of epilepsy in non-responder children, is spreading to be used in the treatment of many diseases, including Alzheimer’s disease. The main activity of the ketogenic diet has been related to improved mitochondrial function and decreased oxidative stress. B-Hydroxybutyrate, the most studied ketone body, has been shown to reduce the production of reactive oxygen species (ROS), improving mitochondrial respiration: it stimulates the cellular endogenous antioxidant system with the activation of nuclear factor erythroid-derived 2-related factor 2 (Nrf2), it modulates the ratio between the oxidized and reduced forms of nicotinamide adenine dinucleotide (NAD+/NADH) and it increases the efficiency of electron transport chain through the expression of uncoupling proteins. Furthermore, the ketogenic diet performs anti-inflammatory activity by inhibiting nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) activation and nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 (NLRP3) inflammasome as well as inhibiting histone deacetylases (HDACs), improving memory encoding. The underlying mechanisms and the perspectives for the treatment of Alzheimer’s disease are discussed

Length of trials in the Italian Judicial System: An Efficiency Analysis by Macro-Area

In recent years, the Italian judicial system has been at the center of both the political debate and policy actions aiming at modifying the territorial structure and the organization of the courts as well as the procedural processes. The measures adopted concerned the reorganization of the magistrates career and the reform of judicial districts. Despite the several reforms, the Italian judicial system does not reach yet the European standards, principally for the so called magistrate-duration procedures binomial, according to which the number of magistrates is above the European average level and the time of legal trials is too long compared with most European countries. Hence, performance and efficiency are worthy of attention in this field. Here, the territorial displacement of efficiency for the Italian judicial districts is studied using a DEA approach followed by a spatial analysis consisting in a PCA for macro-area where the problem of long trials is taken into account. We assess on the geographical characterization of both productivity and expenses of the judicial sector and provide indications in order to improve efficiency according to the dimensions of the courts

Testosterone Replacement Therapy and Cardiovascular Risk: A Review

Recent reports in the scientific and lay press have suggested that testosterone (T) replacement therapy (TRT) is likely to increase cardiovascular (CV) risk. In a final report released in 2015, the Food and Drug Administration (FDA) cautioned that prescribing T products is approved only for men who have low T levels due to primary or secondary hypogonadism resulting from problems within the testis, pituitary, or hypothalamus (e.g., genetic problems or damage from surgery, chemotherapy, or infection). In this report, the FDA emphasized that the benefits and safety of T medications have not been established for the treatment of low T levels due to aging, even if a man's symptoms seem to be related to low T. In this paper, we reviewed the available evidence on the association between TRT and CV risk. In particular, data from randomized controlled studies and information derived from observational and pharmacoepidemiological investigations were scrutinized. The data meta-analyzed here do not support any causal role between TRT and adverse CV events. This is especially true when hypogonadism is properly diagnosed and replacement therapy is correctly performed. Elevated hematocrit represents the most common adverse event related to TRT. Hence, it is important to monitor hematocrit at regular intervals in T-treated subjects in order to avoid potentially serious adverse events

A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer

Our aim was to systematically evaluate the benefits of degarelix as antagonist versus agonists of gonadotropin-releasing hormones (GnRH) for the treatment of advanced prostate cancer (PC). This comparison was performed either in terms of biochemical or oncological or safety profiles. To this end we, carried out a systematic review and meta-analysis of the literature.We selected only studies directly and prospectively analyzing the two treatments in the same population (randomized phase III studies). We followed the Preferred Reporting Items for Systematic Reviews and meta-analyses process for reporting studies.After we eliminated studies according to the exclusion criteria, 9 publications were considered relevant to this review. These articles described 5 clinical trials that were eligible for inclusion. The follow-up duration in all trials did not exceed 364 days. This meta-analysis and review comprised a total of 1719 men, 1061 randomized to degarelix versus 658 to GnRH agonists treatment for advanced PC. Oncological results were evaluated only in 1 trial (CS21:408 cases) and they were not the primary endpoints of the study. Treatment emerging adverse events were reported in 61.4% and 58.8% of patients in the degarelix and GnRH agonists group, respectively (odds ratio, OR = 1.17; 95% confidence interval, 95% CI: 0.78-1.77, P > 0.1). Treatment related severe cardiovascular side effects were reported (trial CS21-30-35) in 1.6% and 3.6% of patients in the degarelix and GnRH agonists group, respectively (OR = 0.55, 95% CI: 0.26-1.14, P > 0.1).Our analysis evidences relevant limitations in particular for the comparative evaluation of the efficacy and the oncological results related to degarelix

Psychological, Relational, and Biological Correlates of Ego-Dystonic Masturbation in a Clinical Setting

AbstractIntroductionAttitudes toward masturbation are extremely varied, and this practice is often perceived with a sense of guilt.AimTo evaluate the prevalence of ego-dystonic masturbation (EM), defined as masturbation activity followed by a sense of guilt, in a clinical setting of sexual medicine and the impact of EM on psychological and relational well-being.MethodsA series of 4,211 men attending an andrology and sexual medicine outpatient clinic was studied retrospectively. The presence and severity of EM were defined according to ANDROTEST items related to masturbation, determined by the mathematical product of the frequency of masturbation and the sense of guilt after masturbation.Main Outcome MeasuresClinical, biochemical, and psychological parameters were studied using the Structured Interview on Erectile Dysfunction, ANDROTEST, and modified Middlesex Hospital Questionnaire.ResultsThree hundred fifty-two subjects (8.4%) reported any sense of guilt after masturbation. Subjects with EM were younger than the remaining sample (mean age ± SD = 51.27 ± 13.43 vs 48.31 ± 12.04 years, P < .0001) and had more psychiatric comorbidities. EM severity was positively associated with higher free-floating (Wald = 35.94, P < .001) and depressive (Wald = 16.85, P < .001) symptoms, and subjects with a higher EM score reported less phobic anxiety (Wald = 4.02, P < .05) and obsessive-compulsive symptoms (Wald = 7.6, P < .01). A higher EM score was associated with a higher alcohol intake. Subjects with EM more often reported the partner's lower frequency of climax and more problems achieving an erection during sexual intercourse. EM severity was positively associated with worse relational and intrapsychic domain scores.ConclusionClinicians should consider that some subjects seeking treatment in a sexual medicine setting might report compulsive sexual behaviors. EM represents a clinically relevant cause of disability, given the high level of psychological distress reported by subjects with this condition, and the severe impact on quality of life in interpersonal relationships

Dimensional reduction of electromagnetism

We derive one- and two-dimensional models for classical electromagnetism by making use of Hadamard’s method of descent. Low-dimensional electromagnetism is conceived as a specialization of the higher-dimensional one, in which the fields are uniform along the additional spatial directions. This strategy yields two independent electromagnetisms in two spatial coordinates and four independent electromagnetisms in one spatial coordinate

Helcococcus kunzii isolated from a sow with purulent urocystitis

Helcococcus kunzii has never been reported in veterinary medicine. The isolation of H. kunzii from a sow with purulent urocystitis is described, suggesting this organism's potential pathogenic role in swine

Dimensional reduction of the Dirac equation in arbitrary spatial dimensions

We investigate the general properties of the dimensional reduction of the Dirac theory, formulated in a Minkowski spacetime with an arbitrary number of spatial dimensions. This is done by applying Hadamard's method of descent, which consists in conceiving low-dimensional theories as a specialization of high-dimensional ones that are uniform along the additional space coordinate. We show that the Dirac equation reduces to either a single Dirac equation or two decoupled Dirac equations, depending on whether the higher-dimensional manifold has even or odd spatial dimensions, respectively. Furthermore, we construct and discuss an explicit hierarchy of representations in which this procedure becomes manifest and can easily be iterated.Comment: 22 pages, several figure